Developing a broad pipeline of precision TYK2 therapeutics
Sudo Biosciences is a Frazier-founded company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. Inhibiting TYK2 has been shown to be beneficial in the treatment of psoriasis, psoriatic arthritis, and lupus. Additional evidence suggests that TYK2 inhibition could provide benefit in an even broader range of autoimmune disorders such as ulcerative colitis, Crohn’s disease, ankylosing spondylitis, multiple sclerosis, and others.